ORIC Pharmaceuticals, Inc.
NASDAQ:ORICBiotechnology
-$0.07 today
- Market cap
- $795.08M
- Beta
- 1.06
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$1.28
Volume 1.39M
Average 1.91M
ORIC EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
ORIC Pharmaceuticals, Inc.NASDAQ: ORIC
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$35.5M, compared with -$29.72M a year earlier. Trailing-twelve-month EBITDA was -$134.03M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 11 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -1.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$35.5M-17.6% QoQ
- Last fiscal yearDec 2025
- -$128.25M-1.2% YoY
- LTMMar 2026
- -$134.03M-1.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -19.4% | +100.0% | +119.4 pp |
| 1 year | -1.2% | +100.0% | +101.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (128.25M) USD
- Year-over-year change
- -1.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (128.25M) | -1.2% |
| FY2024 | 2024-12-31 | (126.74M) | -27.2% |
| FY2023 | 2023-12-31 | (99.67M) | -16.2% |
| FY2022 | 2022-12-31 | (85.8M) | -10.3% |
| FY2021 | 2021-12-31 | (77.82M) | — |
EBITDA vs competitors
How ORIC compares with its peers on the latest reported figures
- ORIC's LTM Mar 2026 EBITDA of -$134.03M is the 8th highest of the 11 companies compared; the peer median is -$124.4M.
- Its year-over-year change of -1.8% is the 3rd highest of 11, against a peer median of -19.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$28.06M | -39.2% | — | — | |
| LTM Mar 2026 | -$42.27M | -2.3% | — | — | |
| LTM Mar 2026 | -$50.64M | -7.0% | — | 32.2% | |
| LTM Mar 2026 | -$112.45M | -48.6% | — | 520.3% | |
| LTM Sep 2026 | -$121.76M | -25.6% | — | — | |
| LTM Jun 2026 | -$127.04M | +36.8% | — | 74.8% | |
| LTM Mar 2026 | -$130.56M | -36.2% | — | — | |
| LTM Mar 2026 | -$134.03M | -1.8% | — | — | |
| LTM Mar 2026 | -$145.24M | -14.0% | — | — | |
| LTM Mar 2026 | -$162.5M | +50.0% | — | 74.8% | |
| LTM Mar 2026 | -$191.95M | -32.3% | — | 387.1% | |
| Peer median (excluding ORIC) | -$124.4M | -19.8% | — | 74.8% | |
Competitors are the stored peer set for ORIC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.03M | 1.11M | 1.22M |
| Gross Profit | 0 | 0 | (1.03M) | (1.11M) | (1.22M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 56.86M | 61.68M | 85.17M | 114.07M | 109.82M |
| Selling, General & Admin | 22.01M | 25.09M | 25.61M | 28.82M | 33.19M |
| Operating Expenses | 78.87M | 91.77M | 109.75M | 141.79M | 141.78M |
| Depreciation & Amortization | 897K | 966K | 1.03M | 1.11M | 1.22M |
| EBITDA | (77.82M) | (85.8M) | (99.67M) | (126.74M) | (128.25M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (78.87M) | (91.77M) | (110.78M) | (142.9M) | (143M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 141K | 2.65M | 10.08M | 0 | 0 |
| Interest Expense | 0 | 2.65M | 0 | 0 | 0 |
| Other Income / Expenses | 156K | 2.65M | 10.08M | 15.05M | 13.54M |
| Income Before Tax | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.07) | (2.25) | (1.96) | (1.83) | (1.47) |
| EPS (Diluted) | (2.07) | (2.25) | (1.96) | (1.83) | (1.47) |
| Weighted Avg Shares | 37.95M | 39.66M | 51.45M | 69.73M | 87.79M |
| Weighted Avg Shares (Diluted) | 37.95M | 39.66M | 51.45M | 69.73M | 87.79M |
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
Intrinsic Alpha fair value
Locked
Current Price
$7.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.